FibroBiologics Inc. (FBLG)
(Delayed Data from NSDQ)
$9.29 USD
+0.55 (6.29%)
Updated May 10, 2024 04:00 PM ET
After-Market: $9.31 +0.02 (0.22%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for FibroBiologics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 2 | 0 | -99,999 | -99,999 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 0 | 0 | 0 | NA | NA |
Total Current Assets | 9 | 3 | 0 | NA | NA |
Net Property & Equipment | 1 | 0 | 0 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 0 | 0 | 0 | NA | NA |
Total Assets | 12 | 5 | 0 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 5 | 2 | NA | NA |
Accounts Payable | 1 | 1 | 0 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 0 | 0 | 0 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 7 | 1 | 0 | NA | NA |
Total Current Liabilities | 9 | 7 | 2 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 0 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 11 | 9 | 2 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 0 | 0 | 0 | NA | NA |
Capital Surplus | 26 | 2 | 0 | NA | NA |
Retained Earnings | -24 | -8 | -3 | NA | NA |
Other Equity | 0 | 1 | 1 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 1 | -4 | -1 | NA | NA |
Total Liabilities & Shareholder's Equity | 12 | 5 | 0 | NA | NA |
Total Common Equity | 1 | -4 | -1 | 0 | 0 |
Shares Outstanding | 32.40 | NA | NA | NA | NA |
Book Value Per Share | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for FibroBiologics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 9 | -99,999 | -99,999 | -99,999 |
Receivables | NA | 0 | NA | NA | NA |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 0 | NA | NA | NA |
Other Current Assets | NA | 0 | NA | NA | NA |
Total Current Assets | NA | 9 | NA | NA | NA |
Net Property & Equipment | NA | 1 | NA | NA | NA |
Investments & Advances | NA | 0 | NA | NA | NA |
Other Non-Current Assets | NA | 0 | NA | NA | NA |
Deferred Charges | NA | 0 | NA | NA | NA |
Intangibles | NA | 0 | NA | NA | NA |
Deposits & Other Assets | NA | 0 | NA | NA | NA |
Total Assets | NA | 12 | NA | NA | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 1 | NA | NA | NA |
Current Portion Long-Term Debt | NA | 0 | NA | NA | NA |
Current Portion Capital Leases | NA | 0 | NA | NA | NA |
Accrued Expenses | NA | 0 | NA | NA | NA |
Income Taxes Payable | NA | 0 | NA | NA | NA |
Other Current Liabilities | NA | 7 | NA | NA | NA |
Total Current Liabilities | NA | 9 | NA | NA | NA |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 0 | NA | NA | NA |
Convertible Debt | NA | 0 | NA | NA | NA |
Long-Term Debt | NA | 0 | NA | NA | NA |
Non-Current Capital Leases | NA | 0 | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | NA | NA | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | NA |
Total Liabilities | NA | 11 | NA | NA | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 0 | NA | NA | NA |
Capital Surplus | NA | 26 | NA | NA | NA |
Retained Earnings | NA | -24 | NA | NA | NA |
Other Equity | NA | 0 | NA | NA | NA |
Treasury Stock | NA | 0 | NA | NA | NA |
Total Shareholder's Equity | NA | 1 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | NA | 12 | NA | NA | NA |
Total Common Equity | 0 | 1 | 0 | 0 | 0 |
Shares Outstanding | 32.60 | 32.40 | NA | NA | NA |
Book Value Per Share | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |